share_log

RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Raises Price Target to $56

RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Raises Price Target to $56

加拿大皇家银行资本维持Xenon Pharmicals跑赢大盘,将目标股价上调至56美元
Benzinga ·  2023/11/28 04:31

RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and raises the price target from $51 to $56.

加拿大皇家银行资本分析师布莱恩·亚伯拉罕斯维持Xenon Pharmicals(纳斯达克股票代码:XENE)跑赢大盘,并将目标股价从51美元上调至56美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发